KARD vs PCRX: stock comparison and AI forecast
Kardigan, Inc. (KARD) and Pacira Biosciences, Inc. (PCRX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
KARD Kardigan, Inc.
- Price
- $15.52 -29.6% · 6M
- Market Cap
- $1.45B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
PCRX Pacira Biosciences, Inc.
- Price
- $36.43 +54.1% · 6M
- Market Cap
- $1.45B
- P/E Ratio
- 49.2x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- KARD and PCRX have similar market capitalizations ($1.45B and $1.45B).
- Over the last six months PCRX returned +54.1% and KARD -29.6%.
- PCRX carries 0.69 times debt per unit of equity, against 0.17 times for KARD.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | KARD | PCRX |
|---|---|---|
| Market Cap | $1.45B | $1.45B |
| P/E Ratio | – | 49.23x |
| P/B Ratio | 2.36x | 2.04x |
| EPS | – | $0.74 |
| Book Value/Share | $6.58 | $17.87 |
| Revenue/Share | – | $18.65 |
| FCF/Share | – | $4.24 |
Profitability & Margins
| Metric | KARD | PCRX |
|---|---|---|
| ROE | – | 5.3% |
| ROA | – | 3.1% |
| ROIC | – | 3.3% |
| Gross Margin | – | 78.7% |
| Operating Margin | – | 4.8% |
| Net Margin | – | 5.1% |
| EBT Margin | – | 5.0% |
| Tax Rate | – | -2.1% |
Financial Health
| Metric | KARD | PCRX |
|---|---|---|
| Current Ratio | 8.72x | 4.68x |
| Quick Ratio | – | 3.65x |
| D/E Ratio | 0.17x | 0.69x |
| Financial Leverage | 1.17x | 1.69x |
| Interest Coverage | – | 7.7x |
| Working Capital | $540M | $464M |
Cash Flow
| Metric | KARD | PCRX |
|---|---|---|
| Operating Cash Flow | – | $177M |
| Free Cash Flow | – | $169M |
| Capital Spending | – | -$8M |
| OCF Growth YoY | – | 25.1% |
| FCF Growth YoY | – | 36.1% |
| FCF/Sales | – | 22.7% |
| CapEx/Sales | – | 1.1% |
Operational Efficiency
| Metric | KARD | PCRX |
|---|---|---|
| Asset Turnover | – | 0.62x |
| Receivables Turnover | – | 6.0x |
| Inventory Turnover | – | 1.2x |
| Fixed Assets Turnover | – | 5.8x |
| Days Sales Outstanding | – | 60 days |
| Days Inventory | – | 299 days |
| Payables Period | – | 40 days |
| Cash Conversion Cycle | – | 319 days |
Income Statement
| Metric | KARD | PCRX |
|---|---|---|
| Total Revenue | – | $743M |
| Operating Income | – | $36M |
| Net Income | – | $38M |
| R&D Expense | – | $123M |
| SG&A Expense | – | $371M |
| Cost of Goods Sold | – | $158M |
Dividend & Shareholder Information
| Metric | KARD | PCRX |
|---|---|---|
| Shares Outstanding | 94M | 40M |
| Net Income Growth | – | 75.5% |
| EPS Growth | – | -31.5% |
KARD vs PCRX: stock comparison and AI forecast
Which is bigger, KARD or PCRX?
KARD and PCRX have similar market capitalizations ($1.45B and $1.45B).
Which stock performed better over the last six months, KARD or PCRX?
Over the last six months PCRX returned +54.1% and KARD -29.6%.
Which one does Intratio's AI model rank higher, KARD or PCRX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.